3 Overrated Stocks with Warning Signs
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. Keeping that in mind, here are three overhyped stocks that may correct and some you should consider instead.
Merit Medical Systems (MMSI)
One-Month Return: +19.4%
Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems (NASDAQ:MMSI) manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy.
Why Is MMSI Not Exciting?
- Subscale operations are evident in its revenue base of $1.58 billion, meaning it has fewer distribution channels than its larger rivals
- ROIC of 5.6% reflects management’s challenges in identifying attractive investment opportunities
Merit Medical Systems’s stock price of $89.74 implies a valuation ratio of 20.8x forward P/E. To fully understand why you should be careful with MMSI, check out our full research report (it’s free).
Fastly (FSLY)
One-Month Return: +41.5%
Taking its name from the core advantage it delivers to customers, Fastly (NASDAQ:FSLY) operates an edge cloud platform that processes, secures, and delivers web content as close to end users as possible, enabling faster digital experiences.
Why Does FSLY Worry Us?
- 13.7% annual revenue growth over the last two years was slower than its software peers
- High servicing costs result in a relatively inferior gross margin of 61.5% that must be offset through increased usage
- Suboptimal cost structure is highlighted by its history of operating margin losses
At $28.97 per share, Fastly trades at 6x forward price-to-sales. Check out our free in-depth research report to learn more about why FSLY doesn’t pass our bar.
Nutanix (NTNX)
One-Month Return: +22.1%
Originally pioneering hyperconverged infrastructure to break down traditional data center silos, Nutanix (NASDAQ:NTNX) provides a unified software platform that enables organizations to run applications and manage data across private, public, and hybrid cloud environments.
Why Are We Cautious About NTNX?
- Products, pricing, or go-to-market strategy may need some adjustments as its 13.5% average billings growth over the last year was weak
- Estimated sales growth of 12.9% for the next 12 months implies demand will slow from its two-year trend
- Operating margin expanded by 3.2 percentage points over the last year as it scaled and became more efficient
Nutanix is trading at $67.31 per share, or 6.2x forward price-to-sales. Dive into our free research report to see why there are better opportunities than NTNX.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.